Guest guest Posted December 1, 2008 Report Share Posted December 1, 2008 Gene-Modified White Blood Cells, Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Refractory or Resistant B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma http://clinicaltrials.gov/ct2/show/NCT00796016 Early. Safety is primary endpoint. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.